S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Okta, Inc: When Great Results Aren’t Good Enough 
NASDAQ:PBLA

Panbela Therapeutics (PBLA) Stock Forecast, Price & News

$6.36
+6.13 (+2,665.22%)
(As of 06/1/2023 ET)
Compare
Today's Range
$5.91
▼
$8.50
50-Day Range
$0.23
▼
$6.36
52-Week Range
$5.91
▼
$1,800.72
Volume
288,061 shs
Average Volume
692,330 shs
Market Capitalization
$106.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Panbela Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
57.2% Upside
$10.00 Price Target
Short Interest
Healthy
4.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Panbela Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.40) to ($1.25) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

603rd out of 1,980 stocks

Pharmaceutical Preparations Industry

281st out of 978 stocks

See Top Rated MarketRank™ Stocks Here

PBLA stock logo

About Panbela Therapeutics (NASDAQ:PBLA) Stock

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm's product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PBLA Stock News Headlines

June 1, 2023 | finance.yahoo.com
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
May 31, 2023 | finance.yahoo.com
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
June 2, 2023 | Edge On The Street (Ad)
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
May 22, 2023 | finance.yahoo.com
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
May 9, 2023 | finance.yahoo.com
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2023 Earnings Call Transcript
May 5, 2023 | marketwatch.com
8-K: Panbela Therapeutics, Inc.
May 5, 2023 | finanznachrichten.de
Panbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q1 2023 Financial Results
May 4, 2023 | msn.com
Panbela Therapeutics: Q1 Earnings Insights
June 2, 2023 | Edge On The Street (Ad)
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
May 4, 2023 | finance.yahoo.com
Panbela Provides Business Update and Reports Q1 2023 Financial Results
May 3, 2023 | americanbankingnews.com
Panbela Therapeutics (PBLA) to Release Quarterly Earnings on Thursday
April 28, 2023 | americanbankingnews.com
Brokers Set Expectations for Panbela Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:PBLA)
April 27, 2023 | americanbankingnews.com
Panbela Therapeutics (NASDAQ:PBLA) Coverage Initiated by Analysts at HC Wainwright
April 26, 2023 | markets.businessinsider.com
Panbela's Game Changer: Analyst Bets Big on Promising Pancreatic Cancer Combatant
April 24, 2023 | finance.yahoo.com
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
April 19, 2023 | msn.com
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 19, 2023 | finance.yahoo.com
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
April 13, 2023 | nasdaq.com
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
April 12, 2023 | msn.com
Why Panbela Therapeutics Shares Are Trading Higher Today
April 12, 2023 | finance.yahoo.com
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
April 12, 2023 | finance.yahoo.com
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
April 11, 2023 | finance.yahoo.com
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
April 10, 2023 | finance.yahoo.com
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
April 6, 2023 | finance.yahoo.com
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
April 3, 2023 | finance.yahoo.com
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
March 22, 2023 | finance.yahoo.com
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
March 22, 2023 | americanbankingnews.com
Panbela Therapeutics (NASDAQ:PBLA) Rating Increased to Buy at Maxim Group
See More Headlines

PBLA Price History

PBLA Company Calendar

Last Earnings
3/16/2023
Today
6/01/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBLA
CUSIP
N/A
CIK
1029125
Web
www.panbela.com
Phone
(952) 479-1196
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+57.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($75.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-34,930,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-3,671.06%
Return on Assets
-442.60%

Debt

Debt-to-Equity Ratio
1.65
Current Ratio
0.80
Quick Ratio
0.80

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.15 per share
Price / Book
42.40

Miscellaneous

Outstanding Shares
16,790,000
Free Float
14,521,000
Market Cap
$106.78 million
Optionable
Not Optionable
Beta
2.03

Key Executives

  • Jennifer K. Simpson
    President, Chief Executive Officer & Director
  • Tammy Groene
    Vice President-Operations
  • Susan Horvath
    Chief Financial Officer, Secretary & Treasurer
  • Elizabeth Bruckheimer
    Chief Scientific Officer & Vice President
  • Rachel Bragg
    Vice President-Clinical Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













PBLA Stock - Frequently Asked Questions

Should I buy or sell Panbela Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBLA shares.
View PBLA analyst ratings or view top-rated stocks.

What is Panbela Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12-month price objectives for Panbela Therapeutics' stock. Their PBLA share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 57.2% from the stock's current price.
View analysts price targets for PBLA or view top-rated stocks among Wall Street analysts.

How have PBLA shares performed in 2023?

Panbela Therapeutics' stock was trading at $0.0733 at the beginning of 2023. Since then, PBLA shares have increased by 8,576.7% and is now trading at $6.36.
View the best growth stocks for 2023 here.

Are investors shorting Panbela Therapeutics?

Panbela Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 754,400 shares, a decline of 59.9% from the April 30th total of 1,880,000 shares. Based on an average daily volume of 2,840,000 shares, the short-interest ratio is presently 0.3 days.
View Panbela Therapeutics' Short Interest.

When is Panbela Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our PBLA earnings forecast.

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($5.68) earnings per share (EPS) for the quarter.

When did Panbela Therapeutics' stock split?

Shares of Panbela Therapeutics reverse split before market open on Thursday, June 1st 2023. The 1-30 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Panbela Therapeutics' stock symbol?

Panbela Therapeutics trades on the NASDAQ under the ticker symbol "PBLA."

Who are Panbela Therapeutics' major shareholders?

Panbela Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (2.54%), CVI Holdings LLC (2.35%), Hudson Bay Capital Management LP (2.11%), Altium Capital Management LP (2.00%), Anson Funds Management LP (0.97%) and Anson Funds Management LP (0.97%).

How do I buy shares of Panbela Therapeutics?

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Panbela Therapeutics' stock price today?

One share of PBLA stock can currently be purchased for approximately $6.36.

How much money does Panbela Therapeutics make?

Panbela Therapeutics (NASDAQ:PBLA) has a market capitalization of $106.78 million. The company earns $-34,930,000.00 in net income (profit) each year or ($75.13) on an earnings per share basis.

How can I contact Panbela Therapeutics?

Panbela Therapeutics' mailing address is 712 VISTA BLVD SUITE 305, WACONIA MN, 55387. The official website for the company is www.panbela.com. The company can be reached via phone at (952) 479-1196 or via email at investors@neoleukin.com.

This page (NASDAQ:PBLA) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -